FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089300560> ?p ?o ?g. }

• W2089300560 endingPage "2185" @default.
• W2089300560 startingPage "2181" @default.
• W2089300560 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Dec 2003Serum Pro Prostate Specific Antigen Improves Cancer Detection Compared to Free and Complexed Prostate Specific Antigen in Men With Prostate Specific Antigen 2 to 4 Ng/Ml WILLIAM J. CATALONA, GEORG BARTSCH, HARRY G. RITTENHOUSE, CINDY L. EVANS, HARRY J. LINTON, ANNA AMIRKHAN, WOLFGANG HORNINGER, HELMUT KLOCKER, and STEPHEN D. MIKOLAJCZYK WILLIAM J. CATALONAWILLIAM J. CATALONA Financial interest and/or other relationship with Beckman Coulter, Inc. Current address: NMSF, Department of Urology, 675 North St. Clair, Suite 20-150, Chicago, Illinois 60611.Supported by Beckman Coulter, Inc. More articles by this author , GEORG BARTSCHGEORG BARTSCH More articles by this author , HARRY G. RITTENHOUSEHARRY G. RITTENHOUSE Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author , CINDY L. EVANSCINDY L. EVANS Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author , HARRY J. LINTONHARRY J. LINTON Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author , ANNA AMIRKHANANNA AMIRKHAN Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author , WOLFGANG HORNINGERWOLFGANG HORNINGER More articles by this author , HELMUT KLOCKERHELMUT KLOCKER More articles by this author , and STEPHEN D. MIKOLAJCZYKSTEPHEN D. MIKOLAJCZYK Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000095460.12999.43AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Pro prostate specific antigen (pPSA) is a precursor form of PSA enriched in tumor compared to benign prostate tissues that may be a more specific serum marker for prostate cancer. Serum pPSA was measured in the clinically relevant early detection PSA range of 2 to 10 ng/ml. Materials and Methods: Research use immunoassays were used to measure native and truncated forms of pPSA. The subject cohort contained 1,091 serum specimens from men enrolled in prostate cancer screening studies at 2 sites who had undergone prostate biopsy and were divided into PSA ranges of 2 to 4 ng/ml (benign 320, cancer 235) and 4 to 10 ng/ml (benign 315, cancer 221). Results: In PSA ranges 2 to 4, 2 to 6, 4 to 10 and 2 to 10 ng/ml, pPSA in a ratio with free PSA (%pPSA) gave the highest cancer specificity. At 2 to 4 ng/ml and 90% sensitivity, %pPSA spared 19% of unnecessary biopsies compared to 10% for free PSA and 11% for complexed PSA(p <0.001). Similar results were obtained at PSA 2 to 6 ng/ml. At 90% sensitivity in the PSA 4 to 10 ng/ml range, %pPSA spared 31% of unnecessary biopsies compared to 20% for % free PSA and 19% for complexed PSA (p <0.0001). In the combined 2 to 10 ng/ml range, %pPSA spared 21% of unnecessary biopsies compared to 13% for % free PSA and 9% for complexed PSA (p <0.0001). Conclusions: The %pPSA significantly improved specificity for cancer detection and decreased the number of unnecessary biopsies in the PSA 2 to 4 ng/ml range. This relative improvement of %pPSA compared to % free PSA and complexed PSA was maintained throughout the PSA range of 2 to 10 ng/ml. References 1 : Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med1991; 324: 1156. Google Scholar 2 : The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am1997; 24: 283. Google Scholar 3 : The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol2001; 166: 845. Link, Google Scholar 4 : Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol2002; 168: 922. Link, Google Scholar 5 : Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. J Urol2001; 165: 1930. Link, Google Scholar 6 : A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res1991; 51: 222. Google Scholar 7 : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA1998; 279: 1542. Google Scholar 8 : Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology1999; 54: 220. Google Scholar 9 : Free prostate-specific antigen in serum is becoming more complex. Urology2002; 59: 797. Google Scholar 10 : A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res2000; 60: 756. Google Scholar 11 : A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology1997; 50: 710. Google Scholar 12 : A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res2001; 61: 6958. Google Scholar 13 : Identification of precursor forms of prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res2001; 61: 957. Google Scholar 14 Khan, M., Partin, A., Rittenhouse, H., Mikolajczyk, S., Sokoll, L., Chan, D. et-al: Evaluation of pro-PSA for early detection of prostate cancer in men with a total PSA range of 4.0–10.0 ng/ml. Unpublished data. Google Scholar 15 : Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis. Urology2003; 61: 274. Google Scholar 16 : Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology2002; 59: 261. Google Scholar 17 : Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol2002; 167: 2017. Link, Google Scholar 18 : Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology2001; 57: 1105. Google Scholar 19 : Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem2002; 35: 471. Google Scholar 20 : Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int2002; 90: 672. Google Scholar From Washington University, St. Louis, Missouri (WJC), University of Innsbruck, Innsbruck, Austria (GB, WH, HK), and Beckman Coulter, Inc., San Diego, California (HGR, CLE, HJL, AA, SDM)© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byEifler J, Sohn W and Barocas D (2018) Review Article: Best Evidence Regarding Contemporary Use of Prostate Cancer BiomarkersUrology Practice, VOL. 3, NO. 3, (210-217), Online publication date: 1-May-2016.Rhodes T, Jacobson D, McGree M, St. Sauver J, Sarma A, Girman C, Lieber M, Klee G, Demissie K and Jacobsen S (2018) Distribution and Associations of [−2]Proenzyme-Prostate Specific Antigen in Community Dwelling Black and White MenJournal of Urology, VOL. 187, NO. 1, (92-96), Online publication date: 1-Jan-2012.Tosoian J, Loeb S, Feng Z, Isharwal S, Landis P, Elliot D, Veltri R, Epstein J, Partin A, Carter H, Trock B and Sokoll L (2018) Association of [−2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate CancerJournal of Urology, VOL. 188, NO. 4, (1131-1136), Online publication date: 1-Oct-2012.Liang Y, Ankerst D, Ketchum N, Ercole B, Shah G, Shaughnessy J, Leach R and Thompson I (2018) Prospective Evaluation of Operating Characteristics of Prostate Cancer Detection BiomarkersJournal of Urology, VOL. 185, NO. 1, (104-110), Online publication date: 1-Jan-2011.Catalona W, Partin A, Sanda M, Wei J, Klee G, Bangma C, Slawin K, Marks L, Loeb S, Broyles D, Shin S, Cruz A, Chan D, Sokoll L, Roberts W, van Schaik R and Mizrahi I (2018) A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen RangeJournal of Urology, VOL. 185, NO. 5, (1650-1655), Online publication date: 1-May-2011.Le B, Griffin C, Loeb S, Carvalhal G, Kan D, Baumann N and Catalona W (2018) [-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening StudyJournal of Urology, VOL. 183, NO. 4, (1355-1359), Online publication date: 1-Apr-2010.Sokoll L, Wang Y, Feng Z, Kagan J, Partin A, Sanda M, Thompson I and Chan D (2018) [-2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation StudyJournal of Urology, VOL. 180, NO. 2, (539-543), Online publication date: 1-Aug-2008.LEIN M, SEMJONOW A, GRAEFEN M, KWIATKOWSKI M, ABRAMJUK C, STEPHAN C, HAESE A, CHUN F, SCHNORR D, LOENING S and JUNG K (2018) A MULTICENTER CLINICAL TRIAL ON THE USE OF (–5, –7) PRO PROSTATE SPECIFIC ANTIGENJournal of Urology, VOL. 174, NO. 6, (2150-2153), Online publication date: 1-Dec-2005.CATALONA W, BARTSCH G, RITTENHOUSE H, EVANS C, LINTON H, HORNINGER W, KLOCKER H and MIKOLAJCZYK S (2018) SERUM PRO-PROSTATE SPECIFIC ANTIGEN PREFERENTIALLY DETECTS AGGRESSIVE PROSTATE CANCERS IN MEN WITH 2 TO 4 NG/ML PROSTATE SPECIFIC ANTIGENJournal of Urology, VOL. 171, NO. 6 Part 1, (2239-2244), Online publication date: 1-Jun-2004. Volume 170Issue 6December 2003Page: 2181-2185 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.Keywordsantibodiesimmunoassayprostatic neoplasmsprostate-specific antigenMetricsAuthor Information WILLIAM J. CATALONA Financial interest and/or other relationship with Beckman Coulter, Inc. Current address: NMSF, Department of Urology, 675 North St. Clair, Suite 20-150, Chicago, Illinois 60611.Supported by Beckman Coulter, Inc. More articles by this author GEORG BARTSCH More articles by this author HARRY G. RITTENHOUSE Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author CINDY L. EVANS Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author HARRY J. LINTON Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author ANNA AMIRKHAN Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author WOLFGANG HORNINGER More articles by this author HELMUT KLOCKER More articles by this author STEPHEN D. MIKOLAJCZYK Financial interest and/or other relationship with Beckman Coulter, Inc. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2089300560 created "2016-06-24" @default.
• W2089300560 creator A5005902264 @default.
• W2089300560 creator A5007595678 @default.
• W2089300560 creator A5008951210 @default.
• W2089300560 creator A5031947478 @default.
• W2089300560 creator A5053870684 @default.
• W2089300560 creator A5065869555 @default.
• W2089300560 creator A5072454263 @default.
• W2089300560 creator A5078373142 @default.
• W2089300560 creator A5089688480 @default.
• W2089300560 date "2003-12-01" @default.
• W2089300560 modified "2023-09-23" @default.
• W2089300560 title "Serum Pro Prostate Specific Antigen Improves Cancer Detection Compared to Free and Complexed Prostate Specific Antigen in Men With Prostate Specific Antigen 2 to 4 Ng/Ml" @default.
• W2089300560 cites W1513820024 @default.
• W2089300560 cites W1979075883 @default.
• W2089300560 cites W1982215657 @default.
• W2089300560 cites W1985784441 @default.
• W2089300560 cites W2006967049 @default.
• W2089300560 cites W2008116325 @default.
• W2089300560 cites W2015115970 @default.
• W2089300560 cites W2020254733 @default.
• W2089300560 cites W2052903206 @default.
• W2089300560 cites W2062234845 @default.
• W2089300560 cites W2079106803 @default.
• W2089300560 cites W2090860076 @default.
• W2089300560 cites W2158002675 @default.
• W2089300560 cites W2171655721 @default.
• W2089300560 cites W2335679869 @default.
• W2089300560 doi "https://doi.org/10.1097/01.ju.0000095460.12999.43" @default.
• W2089300560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14634374" @default.
• W2089300560 hasPublicationYear "2003" @default.
• W2089300560 type Work @default.
• W2089300560 sameAs 2089300560 @default.
• W2089300560 citedByCount "161" @default.
• W2089300560 countsByYear W20893005602012 @default.
• W2089300560 countsByYear W20893005602013 @default.
• W2089300560 countsByYear W20893005602014 @default.
• W2089300560 countsByYear W20893005602015 @default.
• W2089300560 countsByYear W20893005602016 @default.
• W2089300560 countsByYear W20893005602017 @default.
• W2089300560 countsByYear W20893005602018 @default.
• W2089300560 countsByYear W20893005602019 @default.
• W2089300560 countsByYear W20893005602020 @default.
• W2089300560 countsByYear W20893005602023 @default.
• W2089300560 crossrefType "journal-article" @default.
• W2089300560 hasAuthorship W2089300560A5005902264 @default.
• W2089300560 hasAuthorship W2089300560A5007595678 @default.
• W2089300560 hasAuthorship W2089300560A5008951210 @default.
• W2089300560 hasAuthorship W2089300560A5031947478 @default.
• W2089300560 hasAuthorship W2089300560A5053870684 @default.
• W2089300560 hasAuthorship W2089300560A5065869555 @default.
• W2089300560 hasAuthorship W2089300560A5072454263 @default.
• W2089300560 hasAuthorship W2089300560A5078373142 @default.
• W2089300560 hasAuthorship W2089300560A5089688480 @default.
• W2089300560 hasConcept C121608353 @default.
• W2089300560 hasConcept C126322002 @default.
• W2089300560 hasConcept C126894567 @default.
• W2089300560 hasConcept C143998085 @default.
• W2089300560 hasConcept C147483822 @default.
• W2089300560 hasConcept C203014093 @default.
• W2089300560 hasConcept C20417620 @default.
• W2089300560 hasConcept C2776235491 @default.
• W2089300560 hasConcept C2780192828 @default.
• W2089300560 hasConcept C2781406297 @default.
• W2089300560 hasConcept C71924100 @default.
• W2089300560 hasConcept C87874733 @default.
• W2089300560 hasConceptScore W2089300560C121608353 @default.
• W2089300560 hasConceptScore W2089300560C126322002 @default.
• W2089300560 hasConceptScore W2089300560C126894567 @default.
• W2089300560 hasConceptScore W2089300560C143998085 @default.
• W2089300560 hasConceptScore W2089300560C147483822 @default.
• W2089300560 hasConceptScore W2089300560C203014093 @default.
• W2089300560 hasConceptScore W2089300560C20417620 @default.
• W2089300560 hasConceptScore W2089300560C2776235491 @default.
• W2089300560 hasConceptScore W2089300560C2780192828 @default.
• W2089300560 hasConceptScore W2089300560C2781406297 @default.
• W2089300560 hasConceptScore W2089300560C71924100 @default.
• W2089300560 hasConceptScore W2089300560C87874733 @default.
• W2089300560 hasIssue "6" @default.
• W2089300560 hasLocation W20893005601 @default.
• W2089300560 hasLocation W20893005602 @default.
• W2089300560 hasOpenAccess W2089300560 @default.
• W2089300560 hasPrimaryLocation W20893005601 @default.
• W2089300560 hasRelatedWork W1877031100 @default.
• W2089300560 hasRelatedWork W1982816235 @default.
• W2089300560 hasRelatedWork W2055393917 @default.
• W2089300560 hasRelatedWork W2105000714 @default.
• W2089300560 hasRelatedWork W2129795405 @default.
• W2089300560 hasRelatedWork W2361652603 @default.
• W2089300560 hasRelatedWork W2377074263 @default.
• W2089300560 hasRelatedWork W2590637164 @default.
• W2089300560 hasRelatedWork W2897445903 @default.
• W2089300560 hasRelatedWork W4281753098 @default.
• W2089300560 hasVolume "170" @default.
• W2089300560 isParatext "false" @default.
• W2089300560 isRetracted "false" @default.
• W2089300560 magId "2089300560" @default.

• next